🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC

Recruitingn/aAges 18 Years - 80 YearsAllGuangdong Provincial People's Hospital
NCT06771960 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

EGFR-mutated NSCLC is a distinct subtype that responds well to targeted therapies. Neoadjuvant targeted therapy aims to downstage tumors and improve surgical outcomes, but the prognostic role of residual viable tumor (RVT) remains unclear. This retrospective study examines the association between RVT and survival outcomes. The findings will further validate the importance of RVT as a surrogate.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Age 18-80 years old; * Pathologically diagnosed EGFR-mutated non-small cell lung cancer (NSCLC); * Treated with neoadjuvant targeted therapy; * Undergoing definitive surgery. Exclusion Criteria: * A history of prior chemotherapy, immunotherapy, or radiotherapy. * A history of malignancy or lung surgery; * Missing key data.
💊

What it tests

  • Not listed
📍

Where

1 site
Guangdong Provincial People's Hospital
Guangzhou, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy